Skip to main content
Qiagen N.V. logo

Qiagen N.V. — Investor Relations & Filings

Ticker · QIA ISIN · NL0015001WM6 LEI · 54930036WK3GMCN17Z57 F Manufacturing
Open in API
Filings indexed 626 across all filing types
Latest filing 2020-03-03 Regulatory Filings
Country NL Netherlands
Listing F QIA

About Qiagen N.V.

https://www.qiagen.com/

Qiagen N.V. is a global provider of "Sample to Insight" solutions, offering technologies that transform biological materials into valuable molecular insights. The company develops and markets sample and assay technologies, automated instrumentation, and bioinformatics software for molecular diagnostics, applied testing, academic research, and pharmaceutical development. Its comprehensive portfolio supports the entire workflow from sample collection and preparation of DNA, RNA, and proteins to analysis and interpretation. Key product areas include sample preparation kits, PCR, digital PCR (dPCR), and next-generation sequencing (NGS) solutions, as well as syndromic testing panels for infectious diseases.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2020-03-03 English
IRANNOTICE
Regulatory Filings
2020-02-28 English
20-F
Annual Report FY 2019
2020-02-28 English
SEC SCHEDULE 13G
Major Shareholding Notification
2020-02-13 English
SC 13G/A
Major Shareholding Notification
2020-02-12 English
QIAGEN reports results for fourth quarter and full-year 2019
Earnings Release Classification · 98% confidence The document is titled "QIAGEN reports results for fourth quarter and full-year 2019" and contains detailed financial metrics, selected key figures (Net sales, Operating income, EPS), segment breakdowns (product category, geographic region), and management commentary on performance and outlook for 2020. This structure is characteristic of an official announcement of periodic financial results, specifically covering both a quarterly period (Q4 2019) and the full fiscal year (FY 2019). This aligns perfectly with the definition of an Earnings Release (ER), which is the initial announcement of periodical financial results (key highlights only). Although it contains substantial detail, it is the primary release document summarizing the period's performance, distinct from a comprehensive Annual Report (10-K) or a detailed Management Discussion & Analysis (MDA). Given the focus on reporting the period's results immediately after the period ends, ER is the most appropriate classification. Q4 2019
2020-02-05 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.